Similarly, in human primary GIST cells harbouring KIT wt and the KIT‐V559D and KIT‐K642E mutations, nintedanib displayed high potency in a dose‐dependent manner (Fig. 2B, Table S4). The gene discussed is KIT; the disease is gastrointestinal stromal tumor.